Therapeutic technology company Aethlon Medical Inc (Nasdaq:AEMD) stated on Thursday its net loss of USD1.21m (USD0.08 per share) for its fiscal third quarter ended 31 December 2017.
This is compared with a a slight higher net loss of USD1.206m (USD0.15 per share) for the December 2016 quarter.
Revenues of USD74,813 were collected for its fiscal third quarter ended 31 December 2017 under its contract with the National Cancer Institute. It did not have any government contract revenue in the December 2016 quarter.
Consolidated operating expenses for both the three month periods ended 31 December 2017 and 2016 were respectively USD1.24m, as increases in payroll and related expenses and in professional fees were largely offset by a decrease in general and administrative expenses.
Eli Lilly announces Q1 2026 dividend
Amgen announces Q4 2025 dividend
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government